{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:10:26Z","timestamp":1793743826926,"version":"4.6.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/ajp.0b013e318074c986","type":"journal-article","created":{"date-parts":[[2007,6,15]],"date-time":"2007-06-15T04:04:26Z","timestamp":1181880266000},"page":"535-542","source":"Crossref","is-referenced-by-count":118,"title":["Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy\u2014A Retrospective Analysis From the Fabry Outcome Survey"],"prefix":"10.1097","volume":"23","author":[{"given":"Bjoern","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Borsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210204","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"R2-11-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000060196","article-title":"Clinical manifestation in female Fabry disease patients","volume":"36","author":"Whybra","year":"2001","journal-title":"Contrib Nephrol"},{"key":"R3-11-20210204","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"R4-11-20210204","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.32.4.347","article-title":"Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"R5-11-20210204","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Qual Life Res"},{"key":"R6-11-20210204","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual Life Res"},{"key":"R7-11-20210204","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R8-11-20210204","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R9-11-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R10-11-20210204","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"R11-11-20210204","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"R12-11-20210204","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"R13-11-20210204","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"R14-11-20210204","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J Med Genet"},{"key":"R15-11-20210204","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R16-11-20210204","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"R17-11-20210204","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R18-11-20210204","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"R19-11-20210204","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"R20-11-20210204","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/jnnp.36.6.1053","article-title":"Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain","volume":"36","author":"Kahn","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R21-11-20210204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","article-title":"Involvement of dorsal root ganglia in Fabry's disease","volume":"20","author":"Gadoth","year":"1983","journal-title":"J Med Genet"},{"key":"R22-11-20210204","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.410310410","article-title":"Fabry disease: immunocytochemical characterization of neuronal involvement","volume":"31","author":"deVeber","year":"1992","journal-title":"Ann Neurol"},{"key":"R23-11-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(89)90113-5","article-title":"Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry's disease","volume":"90","author":"Hozumi","year":"1989","journal-title":"J Neurol Sci"},{"key":"R24-11-20210204","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archpsyc.1973.04200030090014","article-title":"Psychosis in Fabry disease and treatment with phenoxybenzamine","volume":"29","author":"Liston","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"R25-11-20210204","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2190\/JKFW-3WXK-QA7N-BYLN","article-title":"Psychiatric disorders in patients with Fabry's disease","volume":"23","author":"Grewal","year":"1993","journal-title":"Int J Psychiatry Med"},{"key":"R26-11-20210204","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00041444-200412000-00006","article-title":"Psychiatric findings in four female carriers of Fabry disease","volume":"14","author":"Sadek","year":"2004","journal-title":"Psychiatr Genet"},{"key":"R27-11-20210204","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","article-title":"Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients","volume":"84","author":"Hilz","year":"2000","journal-title":"Pain"},{"key":"R28-11-20210204","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy","volume":"19","author":"Dutsch","year":"2002","journal-title":"J Clin Neurophysiol"},{"key":"R29-11-20210204","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","article-title":"Physiological characterization of neuropathy in Fabry's disease","volume":"26","author":"Luciano","year":"2002","journal-title":"Muscle Nerve"},{"key":"R30-11-20210204","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.54.7.650","article-title":"Ultralate cerebral potentials in a patient with hereditary motor and sensory neuropathy type I indicate preserved C-fibre function","volume":"54","author":"Lankers","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R31-11-20210204","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/brain\/awg070","article-title":"A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis","volume":"126","author":"Rodriguez","year":"2003","journal-title":"Brain"},{"key":"R32-11-20210204","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0016-5085(82)80262-X","article-title":"Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease","volume":"82","author":"O'Brien","year":"1982","journal-title":"Gastroenterology"},{"key":"R33-11-20210204","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-81-5-628","article-title":"Intestinal manifestations of Fabry's disease","volume":"81","author":"Rowe","year":"1974","journal-title":"Ann Intern Med"},{"key":"R34-11-20210204","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0016-5085(84)80028-1","article-title":"Jejunal diverticulosis with perforation as a complication of Fabry's disease","volume":"86","author":"Friedman","year":"1984","journal-title":"Gastroenterology"},{"key":"R36-11-20210204","first-page":"2407","article-title":"Fabry's disease, recommendation for diagnostics, follow up and treatment in Finland","volume":"120","author":"Penttinen","year":"2004","journal-title":"Duodecim"},{"key":"R37-11-20210204","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"R40-11-20210204","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"R41-11-20210204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase. A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am J Hum Genet"}],"container-title":["The Clinical Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002508-200707000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T01:37:48Z","timestamp":1618018668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002508-200707000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ajp.0b013e318074c986","relation":{},"ISSN":["0749-8047"],"issn-type":[{"value":"0749-8047","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}